Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
-
Publication number: 20150132310Abstract: The present invention relates to methods of treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection a subject that involves administering a CD11b inhibitor. The present invention further relates to a non-human transgenic animal expressing human CD11b and its use in methods of identifying novel therapeutics for the treatment and prevention of Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection.Type: ApplicationFiled: March 15, 2013Publication date: May 14, 2015Applicant: NEW YORK UNIVERSITYInventors: Victor J. Torres, Ashley L. Dumont
-
Publication number: 20150132305Abstract: The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer.Type: ApplicationFiled: January 26, 2015Publication date: May 14, 2015Inventor: James G. McArthur
-
Publication number: 20150132253Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: ApplicationFiled: May 21, 2013Publication date: May 14, 2015Applicants: GANYMED PHARMACEUTICALS AG, TRON - Translationale Onkologie an der Johannes Gutenberg-Universitat Mainz gemeinnuetzige GmbHInventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
-
Publication number: 20150132300Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: ApplicationFiled: January 27, 2015Publication date: May 14, 2015Inventors: Yue Yao, Janine Bilsborough
-
Publication number: 20150132224Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: November 18, 2014Publication date: May 14, 2015Inventors: Leon F. GARCIA-MARTINEZ, Ann Elisabeth CARVALHO JENSEN, Katie OLSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH
-
Publication number: 20150132303Abstract: A monoclonal antibody against oncostatin M specific receptor beta subunit, a hybridoma capable of producing the same and a medicament for treating atopic dermatitis comprising the same.Type: ApplicationFiled: May 10, 2013Publication date: May 14, 2015Inventors: Yoshihiro Morikawa, Tadasuke Komori, Eiji Esashi, Ayumi Kotaki
-
Publication number: 20150132311Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.Type: ApplicationFiled: November 12, 2014Publication date: May 14, 2015Inventors: Robert Arch, Jun Zhang, Michelle Madar, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
-
Publication number: 20150132286Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: ApplicationFiled: September 18, 2014Publication date: May 14, 2015Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
-
Publication number: 20150132255Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.Type: ApplicationFiled: June 6, 2013Publication date: May 14, 2015Applicant: Bionor Immuno ASInventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
-
Publication number: 20150132309Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.Type: ApplicationFiled: December 22, 2014Publication date: May 14, 2015Applicant: GENENTECH, INC.Inventor: Luc Desnoyers
-
Publication number: 20150132301Abstract: The present invention provides methods comprising combination therapy for treating cancer. In particular, the present invention provides Wnt pathway inhibitors in combination with MAPK pathway inhibitors for the treatment of cancer and other diseases. In some embodiments, the MAPK pathway signaling activation is due to a mutation in a MAPK pathway component. In some embodiments, the MAPK pathway signaling component is Ras, Raf, MEK, or ERK.Type: ApplicationFiled: December 7, 2012Publication date: May 14, 2015Inventors: Timothy C. Hoey, Christopher Lamond Murriel
-
Patent number: 9028818Abstract: The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.Type: GrantFiled: July 31, 2009Date of Patent: May 12, 2015Assignees: Universite d'Aix-Marseille, Assitance Publique Hôpitaux de MarseilleInventors: L'Houcine Ouafik, Kamel Mabrouk, Itidal Kaafarany, Pierre-Marie Martin
-
Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2
Patent number: 9028819Abstract: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.Type: GrantFiled: March 26, 2013Date of Patent: May 12, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish -
Patent number: 9028820Abstract: The invention relates to monoclonal antibodies directed to a particular part of tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines producing these. Fragments of these antibodies, in particular fragments representing complementarity determining regions (CDRs), and proteins comprising these, are useful in a method of treating cancer, pain, anorexia, anorexia nervosa and/or cachexia.Type: GrantFiled: May 18, 2012Date of Patent: May 12, 2015Assignee: University of BaselInventors: Karl Hofbauer, Jean-Christophe Peter
-
Publication number: 20150125454Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: ApplicationFiled: April 9, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Publication number: 20150125459Abstract: The present disclosure concerns the use of biologically active apelin peptides and compositions that are processed from larger precursor proteins and further post-translationally modified to influence cell growth. Particular methods are useful for promoting cell growth, while others are particularly useful for inhibiting cell growth.Type: ApplicationFiled: January 9, 2015Publication date: May 7, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Frank Cuttitta, Ingalill Avis, David Salomon
-
Publication number: 20150125457Abstract: The present invention provides a bone repair promoter containing as an active ingredient at least one kind of B-type natriuretic peptide receptor agonist.Type: ApplicationFiled: October 24, 2014Publication date: May 7, 2015Inventors: Naomi WAKABAYASHI, Akira YAMAKI, Masako SUGIYAMA
-
Publication number: 20150125514Abstract: A method of diagnosis, prognosis or treatment of an autoimmune disease in a subject wherein the method comprises detecting aquaporin-1 (AQP1), aquaporin-2 (AQP2), aquaporin-5 (AQP5), aquaporin-7 (AQP7) and/or aquaporin-8 (AQP8) autoantibodies in a sample obtained from said subject.Type: ApplicationFiled: August 14, 2012Publication date: May 7, 2015Inventors: Socrates Tzartos, Ioannis Tzartos, Christos Stergiou, Konstantinos Killindreas
-
Publication number: 20150125455Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: ApplicationFiled: September 15, 2014Publication date: May 7, 2015Inventors: Larry L. GREEN, Qing ZHOU, Bruce A. KEYT, Xiao-Dong YANG, Stephen Charles EMERY, David Charles BLAKEY
-
Publication number: 20150125445Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.Type: ApplicationFiled: June 13, 2013Publication date: May 7, 2015Inventors: John C. Herr, Eusebio S. Pires, Austin Herr
-
Publication number: 20150125460Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20150125458Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: ApplicationFiled: November 6, 2014Publication date: May 7, 2015Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
-
Publication number: 20150125453Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.Type: ApplicationFiled: October 25, 2012Publication date: May 7, 2015Applicant: Novartis AGInventors: Sarah Rue, Eckelman Brendan, Deveraux Quinn, Nasoff Marc
-
Publication number: 20150125456Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: October 22, 2014Publication date: May 7, 2015Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Patent number: 9023355Abstract: Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.Type: GrantFiled: February 24, 2012Date of Patent: May 5, 2015Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: David J. Friedman, Martin R. Pollak
-
Patent number: 9023349Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.Type: GrantFiled: June 10, 2013Date of Patent: May 5, 2015Assignee: Rappaport Family Institute for Research in the Medical SciencesInventors: Nathan Karin, Gizi Wildbaum, Rachel Anunu, Yaniv Zohar, Nir Netzer
-
Publication number: 20150118184Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.Type: ApplicationFiled: March 29, 2013Publication date: April 30, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Shigeto Kawai
-
Publication number: 20150118236Abstract: Subject of the present invention is a method for predicting the risk of getting a cardiovascular event in a female subject comprising determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro-neurotensin or fragments thereof with the a risk for getting a cardiovascular event, wherein an elevated level is predictive for an enhanced risk of getting a cardiovascular event.Type: ApplicationFiled: March 8, 2013Publication date: April 30, 2015Inventors: Andreas Bergmann, Olle Melander
-
Publication number: 20150118237Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: April 23, 2013Publication date: April 30, 2015Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20150118243Abstract: Methods and compositions for identifying, diagnosing, and treating neuroblastoma are disclosed.Type: ApplicationFiled: January 15, 2015Publication date: April 30, 2015Inventors: John M. Maris, Yael P. Mosse, Erica L. Carpenter
-
Publication number: 20150118239Abstract: The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric oligomers, wherein said antibody molecule does not bind human monomeric A? 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.Type: ApplicationFiled: May 8, 2013Publication date: April 30, 2015Applicant: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZINInventor: Thomas Bayer
-
Publication number: 20150118242Abstract: A specific epitope on the surface of the hepatitis C virus that induces a neutralizing antibody response in vivo and neutralizing monoclonal antibodies that bind specifically to the epitope are disclosed. The antibodies block hepatitis C virus from infecting cells.Type: ApplicationFiled: May 16, 2013Publication date: April 30, 2015Inventors: Hongying Duan, Stephen M. Feinstone, Marian Major, Pei Zhang
-
Publication number: 20150118232Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: ApplicationFiled: September 26, 2014Publication date: April 30, 2015Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Publication number: 20150118241Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.Type: ApplicationFiled: May 14, 2013Publication date: April 30, 2015Inventors: Sha Mi, R. Blake Pepinsky
-
Publication number: 20150118240Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: May 13, 2013Publication date: April 30, 2015Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
-
Publication number: 20150118238Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.Type: ApplicationFiled: May 1, 2013Publication date: April 30, 2015Inventors: Gregory Beuerlein, Julian Davies, Irene Jennifer Denning, Ling Liu, Jirong Lu, Peter Edward Vaillancourt
-
Publication number: 20150118235Abstract: An antibody that binds a MeCP2E1 isoform of MeCP2 protein, wherein the antibody comprises a region comprising the amino acid sequence of SEQ ID NO:4. A method for detecting and/or monitoring a disease or a disorder caused by an over-expression or an under-expression of a MeCP2E1 isoform of MeCP2 protein, comprising the steps of: (i) obtaining a first sample from a mammalian subject; (ii) contacting the first sample with the anti-MeCP2E1antibody; (iii) removing unbound antibody from the sample; (iv) conducting an immunoassay on the first sample to determine a first value for expression of the MeCP2E1 isoform; (v) comparing the first value to a reference value for expression of the MeCP2E1 isoform in healthy mammalian subjects; wherein a deviation of the first value from the reference value indicates the presence of a disease or a disorder caused by an over-expression or an under-expression of the MeCP2E1 isoform.Type: ApplicationFiled: October 24, 2013Publication date: April 30, 2015Applicant: University of ManitobaInventor: Mojgan Rastegar
-
Patent number: 9017670Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.Type: GrantFiled: August 16, 2012Date of Patent: April 28, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Gavin Thurston
-
Publication number: 20150110791Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.Type: ApplicationFiled: May 20, 2014Publication date: April 23, 2015Applicant: GENENTECH, INC.Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
-
Publication number: 20150110792Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.Type: ApplicationFiled: November 16, 2012Publication date: April 23, 2015Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
-
Publication number: 20150110783Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.Type: ApplicationFiled: December 18, 2014Publication date: April 23, 2015Applicants: XOMA Technology Ltd., NOVARTIS AGInventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
-
Publication number: 20150110796Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: September 30, 2014Publication date: April 23, 2015Applicant: ABLYNX N.V.Inventors: FRANCIS DESCAMPS, MARIA GONZALEZ PAJUELO, PASCAL GERARD MERCHIERS, CATELIJNE STORTELERS, PETER VANLANDSCHOOT, PHILIPPE VAN ROMPAEY, MARTINE SMIT, REGORIUS LEURS, DAVID ANDRE BAPTISTE MAUSSANG-DETAILLE
-
Publication number: 20150110786Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.Type: ApplicationFiled: March 7, 2013Publication date: April 23, 2015Inventors: Deborah Fass, Iris Grossman, Tal Ilani, Assaf Alon
-
Publication number: 20150110777Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.Type: ApplicationFiled: July 11, 2014Publication date: April 23, 2015Inventors: Robin Barbour, Yue Liu
-
Publication number: 20150110798Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FR?.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Philip S. Low, Dimiter S. Dimitrov, Yang Feng, Jiayin Shen
-
Publication number: 20150110797Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.Type: ApplicationFiled: September 30, 2014Publication date: April 23, 2015Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
-
Publication number: 20150110794Abstract: This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In another aspect, the disclosure features therapeutic, prophylactic, and/or diagnostic compositions for human cytomegalovirus infection or for a human cytomegalovirus-related disease that include a binding agent (e.g., antibody) or polynucleotide disclosed herein. In some embodiments, the composition is formulated for ocular or topical administration. The compositions can further include one or more human cytomegalovirus-neutralizing antibodies, an intravenous immunoglobulin preparation, and/or one or more antiviral compounds (e.g., ganciclovir, foscamet, cidofovir, or valganciclovir).Type: ApplicationFiled: April 30, 2013Publication date: April 23, 2015Inventors: Shuji Sato, Sean Andre Beausoleil, Wan Cheung Cheung, Roberto D. Polakiewicz
-
Publication number: 20150110795Abstract: Antibodies for use in the treatment and/or prevention of retinal diseases, in particular a retinal disease that curses with dysfunction of the external blood-retinal barrier, the dysfunction being an alteration or impairment of the blood-retinal barrier for any etiology. Pharmaceutical and veterinary compositions are also disclosed in which the antibodies are present. The compositions may be applied in wide spectra of ocular diseases.Type: ApplicationFiled: April 29, 2013Publication date: April 23, 2015Applicant: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCAInventors: Cristina Hernández Pascual, Rafael Simó Canonge
-
Publication number: 20150110793Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.Type: ApplicationFiled: December 28, 2012Publication date: April 23, 2015Inventors: Hirotake Shiraiwa, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
-
Patent number: 9012151Abstract: The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.Type: GrantFiled: November 8, 2007Date of Patent: April 21, 2015Assignee: B.R.A.H.M.S. GmbHInventors: Leong Loke Ng, Andreas Bergmann, Joachim Struck, Nils Morgenthaler, Jana Papassotiriou